Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Oral GLP-1 Pionee | Structure Therapeutics leads the charge in developing oral treatments for diabetes and obesity, with aleniglipron showing promise in the competitive GLP-1 market |
Pipeline Potential | Explore GPCR's robust pipeline, including aleniglipron and ACCG-2671, poised to disrupt the metabolic disease treatment landscape with oral formulations |
Market Dynamics | Delve into Structure Therapeutics' strategic positioning amidst fierce competition from pharma giants, leveraging its focus on oral small molecule therapies |
Financial Outlook | Analyst price targets range from $37.50 to $120 per share, reflecting optimism about GPCR's potential in the expanding GLP-1 receptor agonist market |
Metrics to compare | GPCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGPCRPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.3x | −0.5x | −0.6x | |
PEG Ratio | 0.16 | 0.10 | 0.00 | |
Price/Book | 1.5x | 2.3x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | 231.5% | 153.9% | 38.0% | |
Fair Value Upside | Unlock | 9.3% | 4.4% | Unlock |